Meeting
2018 ASCO Annual Meeting
Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer.
Authors
Rashmi Krishna Murthy
University of Texas MD Anderson Cancer Center, Houston, TX
Rashmi Krishna Murthy , Erika Paige Hamilton , Cristiano Ferrario , Nathalie Aucoin , Carla Isadora Falkson , Marc C. Chamberlain , Todd Gray , Virginia F. Borges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT01983501 and NCT02025192
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1015)
DOI
10.1200/JCO.2018.36.15_suppl.1015
Abstract #
1015
Poster Bd #
96
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2017 ASCO Annual Meeting
A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).
First Author: Carey K. Anders
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton